Personalized Antiseizure Medication Therapy in Critically Ill Adult Patients
Online ahead of print.
Item in Clipboard
Precision medicine has the potential to have a significant impact on both drug development and patient care. It is crucial to not only provide prompt effective antiseizure treatment for critically ill patients after seizures start, but to also have a proactive mindset and concentrate on epileptogenesis and the underlying cause of the seizures or seizure disorder. Critical illness presents different treatment issues compared to the ambulatory population, which makes it challenging to choose the best antiseizure medications and to administer them at the right time and at the right dose. Since there is a paucity of information available on antiseizure medication dosing in critically ill patients, therapeutic drug monitoring is a useful tool for defining each patient’s personal therapeutic range and assisting clinicians in decision making. Use of pharmacogenomic information relating to pharmacokinetics, hepatic metabolism, and seizure etiology may improve safety and efficacy by individualizing therapy. Studies evaluating clinical implementation of pharmacogenomic information at the point of care and identification of biomarkers are also needed. These studies may make it possible to avoid adverse drug reactions, maximize drug efficacy, reduce drug-drug interactions, and optimize medications for each individual patient. This review will discuss the available literature and provide future insights on precision medicine use with antiseizure therapy in critically ill adult patients.
Precision medicine; antiseizure medication; biomarker; intensive care unit (ICU); pharmacogenomics; pharmacokinetics; seizure.
This article is protected by copyright. All rights reserved.